Eupraxia Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Eupraxia Pharmaceuticals Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
Eupraxia Pharmaceuticals Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds38 adding, 23 cuttingOf 13 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 4.6% while net income fell 51.3%: a 56pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Eupraxia Pharmaceuticals Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 17.8% in a year.
Latest results
- Earnings per share
- -$0.23 against an average estimate of -$0.23: beat by 0.0%
- Next report
- November 3, 2026; average EPS estimate -$0.26
Price chart
- 1 day-1.0%
- 1 week-1.3%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $0
- EPS (TTM, diluted)
- $-0.97
Growth
- Share count change
- +17.8%
Cash
- Free cash flow (TTM)
- -$28.8M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for EPRX from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Eupraxia Pharmaceuticals Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.0 ~$0.0–$0.2 | Left out: out of range vs price (0.01x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Eupraxia Pharmaceuticals Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 3, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.26 (range −$0.32 to −$0.22) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.98 | +5% | — | 0% |
| Next | −$1.04 | −6% | $709820 | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +0.5% on 90 days ago. In the last 30 days, 1 analyst raised Eupraxia Pharmaceuticals Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.97 | −$0.90 |
| 60 days ago | −$0.97 | −$1.04 |
| 30 days ago | −$0.97 | −$1.04 |
| 7 days ago | −$0.97 | −$1.04 |
| Now | −$0.98 | −$1.04 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.23 | −$0.23 | 0.0% |
| Dec 2025 | −$0.16 | −$0.37 | −133.3% |
| Sept 2025 | −$0.19 | −$0.19 | +1.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- — of tradable shares
- Days to cover
- 7.17 at average volume
- Short interest, 1 month
- −14% to October 15, 2026
- Held by institutions
- 43% of shares
- Held by insiders
- 12.1% of shares
- Employees
- 49 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 0 | 0 |
| Net income | −28 | −26 | −39 |
| Diluted EPS | −$1.17 | −$0.76 | −$1.03 |
| Cash flow | |||
| Cash from operations | −21 | −30 | −29 |
| Stock-based pay | 1 | 3 | 9 |
| Balance sheet | |||
| Cash | 19 | 33 | 81 |
| Total debt | — | 0 | 0 |
| Net debt (negative = net cash) | −19 | −33 | −81 |
| Diluted shares | 24m | 34m | 40m |
Financial health
- Short-term assets cover short-term liabilities $85m of assets due within a year against $6m of liabilities due within a year.
- Short-term assets cover long-term liabilities $85m short-term assets against $75,910 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +17.8%
- year over year
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Change in share count Balance sheet | 17.8% | 7.9% | 112 of 156 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
Funds buying and selling- Reported value
- $164M
- Institutions reporting
- 68
- Shares held vs prior quarter
- ▲ 11.6%
- Positions opened / closed
- 16 / 5
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | $23.8M | 3.6M | 14.5% | ▼ 1.1% |
| Affinity Asset Advisors, LLC | $10.9M | 1.6M | 6.7% | ▲ 3.8% |
| Balyasny Asset Management L.P. | $8.9M | 1.4M | 5.5% | 0.0% |
| Vivo Capital, LLC | $8.9M | 1.4M | 5.5% | 0.0% |
| Scotia Capital Inc. | $8.8M | 1.3M | 5.4% | ▲ 0.1% |
| Pfm Health Sciences, LP | $8M | 1.2M | 4.9% | ▲ 123.8% |
| Great Point Partners LLC | $7.9M | 1.2M | 4.8% | 0.0% |
| Jupiter Topco LLC | $6.9M | 1.0M | 4.2% | — |
| Rubric Capital Management LP | $5.7M | 867K | 3.5% | ▲ 25.5% |
| Ikarian Capital, LLC | $5.4M | 810K | 3.3% | ▼ 33.3% |
| Woodline Partners LP | $4.9M | 747K | 3.0% | ▲ 69.5% |
| Point72 Asset Management, L.P. | $4.8M | 730K | 3.0% | ▼ 24.5% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Eupraxia Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Eupraxia Pharmaceuticals Inc. in brief
- What does Eupraxia Pharmaceuticals Inc. do?
- Eupraxia Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Eupraxia Pharmaceuticals Inc.'s stock ticker?
- Eupraxia Pharmaceuticals Inc. trades under the ticker EPRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Eupraxia Pharmaceuticals Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Beutel, Goodman & Co Ltd., Affinity Asset Advisors, LLC and Balyasny Asset Management L.P. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Eupraxia Pharmaceuticals Inc.'s next earnings date?
- Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Eupraxia Pharmaceuticals Inc. announces its own schedule.
Follow research on Eupraxia Pharmaceuticals Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.